@article{corpechot:hal-03590930,
TITLE = {A 2-year multicenter, double-blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid therapy (Bezurso)},
AUTHOR = {Corpechot, C. and Chazouilleres, O. and Rousseau, A. and Guyader, D. and Habersetzer, F. and Mathurin, P. and Goria, O. and Potier, P. and Minello, A. and Silvain, C. and Abergel, A. and Debette-Gratien, M. and Larrey, D. and Roux, O. and Bronowicki, J. -P. and Boursier, J. and de Ledhingen, V. and Heurgue-Berlot, A. and Nguyen-Khac, Eric and Zoulim, F. and Ollivier-Hourmand, I. and Zarski, J. -P. and Nkontchou, G. and Gaouar, F. and Simon, T. and Poupon, R.},
URL = {https://u-picardie.hal.science/hal-03590930},
NOTE = {International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver-Disease, Amsterdam, NETHERLANDS, APR 19-23, 2017},
JOURNAL = {Journal of Hepatology},
PUBLISHER = {Elsevier},
VOLUME = {66},
NUMBER = {1, S},
PAGES = {S89},
YEAR = {2017},
DOI = {10.1016/S0168-8278(17)30442-7},
HAL_ID = {hal-03590930},
HAL_VERSION = {v1},
}